January 19, 2016

Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancreatic Cancer

Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of gemcitabine-treated historical controls Of the evaluable tumors, 30 percent had partial response and another 30 percent had stable disease January 19, 2016… Read More
learn more
January 11, 2016

Novocure Announces Preliminary 2015 Operating Statistics

555 prescriptions were received in the fourth quarter of 2015, an increase of 108% versus the prior year quarter 603 active patients at December 31, 2015, an increase of 168% versus December 31, 2014 January 11, 2016 07:30 AM Eastern Standard Time ST. HELIER, Jersey–(… Read More
learn more
January 7, 2016

Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients

January 07, 2016 04:15 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it submitted a premarket approval (PMA) partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Optune, a Tumor Treating Fields (TTFields) therapy delivery device,… Read More
learn more
January 6, 2016

Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System

Second generation Tumor Treating Fields delivery system is more than 50 percent lighter and 50 percent smaller than first generation Optune January 06, 2016 08:24 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) filed a premarket approval (PMA) supplement application for its new,… Read More
learn more
January 4, 2016

Novocure to Participate in 34th Annual J.P. Morgan Healthcare Conference

January 04, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate in the 34th Annual J.P. Morgan Healthcare Conference on Jan. 13, 2016, in San Francisco. Bill Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Read More
learn more